CD4-CD8- T cell receptor αβ T cells

Generation of an in vitro major histocompatability complex class I specific cytotoxic T lymphocyte response and allogeneic tumor rejection

Masahiro Mieno, Ryuichiro Suto, Yuichi Obata, Heiichiro Udono, Toshitada Takahashi, Hiroshi Shiku, Eiichi Nakayama

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

The generation of an in vitro major histocompatibility complex class I specifie response of CD4-CD8- T cell receptor (TCR) αβ cytotoxic T lymphocytes (CTL) and their allogeneic tumor rejection were investigated. Inocula of BALBRL♂ 1 were rejected in C57BL/6 (B6) mice treated with minimum essential medium (MEM) (control), anti-L3T4 (CD4) monoclonal antibody (mAb) or anti-Lyt-2.2 (CD8) mAb and CTL against the tumor were generated in vitro. No rejection and no induction of CTL were observed in B6 mice treated with anti-L3T4 (CD4) plus anti-Lyt-2.2 (CD8) mAb. CTL with the classical Thy-1+CD3+CD4-CD8+ TCR αβ phenotype were generated in mixed lymphocyte tumor cell culture (MLTC) spleen cells from B6 mice treated with MEM (control) or anti-L3T4 (CD4) mAb, whereas CTL with an unusual Thy-1+ CD3+ CD4-CD8- TCR αβ phenotype were generated in MLTC spleen cells from anti-Lyt-2.2 (CD8) mAb-treated B6 mice. Both types of CTL were reactive with both H-2Kd and Dd (Ld) class I antigen. These findings suggest that when CD4+ cells were blocked by antiL3T4 (CD4) mAb, CD8+ CTL mediated rejection, and when CD8+ cells were blocked by anti-Lyt-2.2 (CD8) mAb, CD4+ cells were capable of mediating rejection, although less efficiently than CD8+ cells, by inducing CD4-CD8+ TCR αβ CTL. The finding that adoptive transfer of CD4 and CD8-depleted MLTC spleen cells, obtained from anti-Lyt-2.2 (CD8) mAbtreated B6 mice that had rejected BALBRL♂ 1, resulted in rejection of BALBRL♂ 1 inoculated into B6 nu/nu mice confirmed the above notion. CTL clones with the CD4-CD8- TCR αβ phenotype specific for Ld were established.

Original languageEnglish
Pages (from-to)193-201
Number of pages9
JournalJournal of Experimental Medicine
Volume174
Issue number1
Publication statusPublished - 1991
Externally publishedYes

Fingerprint

Cytotoxic T-Lymphocytes
T-Cell Antigen Receptor
T-Lymphocytes
Monoclonal Antibodies
Neoplasms
Spleen
Cell Culture Techniques
Lymphocytes
Phenotype
In Vitro Techniques
Histocompatibility Antigens Class I
Adoptive Transfer
Major Histocompatibility Complex
Clone Cells

ASJC Scopus subject areas

  • Immunology

Cite this

CD4-CD8- T cell receptor αβ T cells : Generation of an in vitro major histocompatability complex class I specific cytotoxic T lymphocyte response and allogeneic tumor rejection. / Mieno, Masahiro; Suto, Ryuichiro; Obata, Yuichi; Udono, Heiichiro; Takahashi, Toshitada; Shiku, Hiroshi; Nakayama, Eiichi.

In: Journal of Experimental Medicine, Vol. 174, No. 1, 1991, p. 193-201.

Research output: Contribution to journalArticle

Mieno, Masahiro ; Suto, Ryuichiro ; Obata, Yuichi ; Udono, Heiichiro ; Takahashi, Toshitada ; Shiku, Hiroshi ; Nakayama, Eiichi. / CD4-CD8- T cell receptor αβ T cells : Generation of an in vitro major histocompatability complex class I specific cytotoxic T lymphocyte response and allogeneic tumor rejection. In: Journal of Experimental Medicine. 1991 ; Vol. 174, No. 1. pp. 193-201.
@article{49d4c3447dcf4001973caf4cb6e6fff5,
title = "CD4-CD8- T cell receptor αβ T cells: Generation of an in vitro major histocompatability complex class I specific cytotoxic T lymphocyte response and allogeneic tumor rejection",
abstract = "The generation of an in vitro major histocompatibility complex class I specifie response of CD4-CD8- T cell receptor (TCR) αβ cytotoxic T lymphocytes (CTL) and their allogeneic tumor rejection were investigated. Inocula of BALBRL♂ 1 were rejected in C57BL/6 (B6) mice treated with minimum essential medium (MEM) (control), anti-L3T4 (CD4) monoclonal antibody (mAb) or anti-Lyt-2.2 (CD8) mAb and CTL against the tumor were generated in vitro. No rejection and no induction of CTL were observed in B6 mice treated with anti-L3T4 (CD4) plus anti-Lyt-2.2 (CD8) mAb. CTL with the classical Thy-1+CD3+CD4-CD8+ TCR αβ phenotype were generated in mixed lymphocyte tumor cell culture (MLTC) spleen cells from B6 mice treated with MEM (control) or anti-L3T4 (CD4) mAb, whereas CTL with an unusual Thy-1+ CD3+ CD4-CD8- TCR αβ phenotype were generated in MLTC spleen cells from anti-Lyt-2.2 (CD8) mAb-treated B6 mice. Both types of CTL were reactive with both H-2Kd and Dd (Ld) class I antigen. These findings suggest that when CD4+ cells were blocked by antiL3T4 (CD4) mAb, CD8+ CTL mediated rejection, and when CD8+ cells were blocked by anti-Lyt-2.2 (CD8) mAb, CD4+ cells were capable of mediating rejection, although less efficiently than CD8+ cells, by inducing CD4-CD8+ TCR αβ CTL. The finding that adoptive transfer of CD4 and CD8-depleted MLTC spleen cells, obtained from anti-Lyt-2.2 (CD8) mAbtreated B6 mice that had rejected BALBRL♂ 1, resulted in rejection of BALBRL♂ 1 inoculated into B6 nu/nu mice confirmed the above notion. CTL clones with the CD4-CD8- TCR αβ phenotype specific for Ld were established.",
author = "Masahiro Mieno and Ryuichiro Suto and Yuichi Obata and Heiichiro Udono and Toshitada Takahashi and Hiroshi Shiku and Eiichi Nakayama",
year = "1991",
language = "English",
volume = "174",
pages = "193--201",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "1",

}

TY - JOUR

T1 - CD4-CD8- T cell receptor αβ T cells

T2 - Generation of an in vitro major histocompatability complex class I specific cytotoxic T lymphocyte response and allogeneic tumor rejection

AU - Mieno, Masahiro

AU - Suto, Ryuichiro

AU - Obata, Yuichi

AU - Udono, Heiichiro

AU - Takahashi, Toshitada

AU - Shiku, Hiroshi

AU - Nakayama, Eiichi

PY - 1991

Y1 - 1991

N2 - The generation of an in vitro major histocompatibility complex class I specifie response of CD4-CD8- T cell receptor (TCR) αβ cytotoxic T lymphocytes (CTL) and their allogeneic tumor rejection were investigated. Inocula of BALBRL♂ 1 were rejected in C57BL/6 (B6) mice treated with minimum essential medium (MEM) (control), anti-L3T4 (CD4) monoclonal antibody (mAb) or anti-Lyt-2.2 (CD8) mAb and CTL against the tumor were generated in vitro. No rejection and no induction of CTL were observed in B6 mice treated with anti-L3T4 (CD4) plus anti-Lyt-2.2 (CD8) mAb. CTL with the classical Thy-1+CD3+CD4-CD8+ TCR αβ phenotype were generated in mixed lymphocyte tumor cell culture (MLTC) spleen cells from B6 mice treated with MEM (control) or anti-L3T4 (CD4) mAb, whereas CTL with an unusual Thy-1+ CD3+ CD4-CD8- TCR αβ phenotype were generated in MLTC spleen cells from anti-Lyt-2.2 (CD8) mAb-treated B6 mice. Both types of CTL were reactive with both H-2Kd and Dd (Ld) class I antigen. These findings suggest that when CD4+ cells were blocked by antiL3T4 (CD4) mAb, CD8+ CTL mediated rejection, and when CD8+ cells were blocked by anti-Lyt-2.2 (CD8) mAb, CD4+ cells were capable of mediating rejection, although less efficiently than CD8+ cells, by inducing CD4-CD8+ TCR αβ CTL. The finding that adoptive transfer of CD4 and CD8-depleted MLTC spleen cells, obtained from anti-Lyt-2.2 (CD8) mAbtreated B6 mice that had rejected BALBRL♂ 1, resulted in rejection of BALBRL♂ 1 inoculated into B6 nu/nu mice confirmed the above notion. CTL clones with the CD4-CD8- TCR αβ phenotype specific for Ld were established.

AB - The generation of an in vitro major histocompatibility complex class I specifie response of CD4-CD8- T cell receptor (TCR) αβ cytotoxic T lymphocytes (CTL) and their allogeneic tumor rejection were investigated. Inocula of BALBRL♂ 1 were rejected in C57BL/6 (B6) mice treated with minimum essential medium (MEM) (control), anti-L3T4 (CD4) monoclonal antibody (mAb) or anti-Lyt-2.2 (CD8) mAb and CTL against the tumor were generated in vitro. No rejection and no induction of CTL were observed in B6 mice treated with anti-L3T4 (CD4) plus anti-Lyt-2.2 (CD8) mAb. CTL with the classical Thy-1+CD3+CD4-CD8+ TCR αβ phenotype were generated in mixed lymphocyte tumor cell culture (MLTC) spleen cells from B6 mice treated with MEM (control) or anti-L3T4 (CD4) mAb, whereas CTL with an unusual Thy-1+ CD3+ CD4-CD8- TCR αβ phenotype were generated in MLTC spleen cells from anti-Lyt-2.2 (CD8) mAb-treated B6 mice. Both types of CTL were reactive with both H-2Kd and Dd (Ld) class I antigen. These findings suggest that when CD4+ cells were blocked by antiL3T4 (CD4) mAb, CD8+ CTL mediated rejection, and when CD8+ cells were blocked by anti-Lyt-2.2 (CD8) mAb, CD4+ cells were capable of mediating rejection, although less efficiently than CD8+ cells, by inducing CD4-CD8+ TCR αβ CTL. The finding that adoptive transfer of CD4 and CD8-depleted MLTC spleen cells, obtained from anti-Lyt-2.2 (CD8) mAbtreated B6 mice that had rejected BALBRL♂ 1, resulted in rejection of BALBRL♂ 1 inoculated into B6 nu/nu mice confirmed the above notion. CTL clones with the CD4-CD8- TCR αβ phenotype specific for Ld were established.

UR - http://www.scopus.com/inward/record.url?scp=0025822209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025822209&partnerID=8YFLogxK

M3 - Article

VL - 174

SP - 193

EP - 201

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 1

ER -